{"success":true,"data":{"pressRelease":{"id":"173972","rtpr_id":"nBwbktT25a-20261020","ticker":"WGS","exchange":"NASDAQ","all_tickers":["WGS"],"title":"GeneDx Expands Diagnostic Leadership with Long-Read Genome Sequencing, Advancing Rare Disease Diagnosis","author":"Business Wire","published_at":"2026-10-20T12:30:00.323Z","article_body":"GeneDx Expands Diagnostic Leadership with Long-Read Genome Sequencing,\nAdvancing Rare Disease Diagnosis\n\nGeneDx combines clinical expertise with a phenotype-driven approach to solve\ncomplex genetic cases and deliver answers sooner\n\nGeneDx (Nasdaq: WGS), the leader in rare disease diagnosis and improving\nhealth through the power of genomic data, today announced plans to enhance its\ngenome testing portfolio with long-read whole genome sequencing (lrWGS).\n\nLong-read sequencing analyzes longer stretches of DNA to identify complex\ngenetic variation, including certain structural variants and repeat expansions\nthat can go undetected by traditional short-read sequencing. With years of\npublished research(1) and collaborations with leading technology partners,\nGeneDx is uniquely positioned to bring long-read sequencing into clinical\npractice, combining advanced sequencing of genomic data, rich phenotypic data,\nand deep clinical expertise to deliver meaningful answers for patients.\n\nLeveraging insights from GeneDx Infinity™ and decades of clinical\ninterpretation, GeneDx will identify where long-read sequencing can deliver\nthe greatest diagnostic value and offer lrWGS upfront for eligible patients.\nThis targeted, phenotype-driven approach aims to reduce sequential testing,\nclose diagnostic gaps and accelerate diagnosis.\n\n“Long-read sequencing is providing us with substantially more powerful\ninsights into the human genome than previously possible. We are especially\ninterested in how this technology helps us to understand the cause of a\npatient’s rare disease when their genome is from a population that has been\nunder-studied,” said John Greally, D.Med., Ph.D., chief of genomics, and\nprofessor of genetics and pediatrics at Albert Einstein College of Medicine,\nclinical geneticist at the Children's Hospital at Montefiore (CHAM), and\nco-director of the NY Center for Rare Diseases at Montefiore. “The future\nfor rare disease diagnostics combines long-read sequencing with enhanced\nclinical information describing the patient, adding the expertise of\nclinicians to the solution, finally providing answers for patients and\nfamilies living with these conditions.”\n\n“Every advancement in genomic medicine should bring patients closer to\nanswers,” said Linda Genen, MD, MPH, Chief Medical Officer, GeneDx.\n“Long-read sequencing creates new opportunities to uncover complex genetic\nvariation, but the true value lies in how those findings are interpreted and\napplied. By combining advanced sequencing with our deep genomic data and\nclinical expertise, we aim to equip clinicians with clearer insights to\nnavigate complex cases, make more informed diagnostic decisions and get\npatients closer to answers.”\n\nThe early access program will be available by year-end and is part of GeneDx's\ncontinued focus on genome innovation to expand diagnostic capabilities and\ndeliver more answers to more patients. To learn more, contact our team at\ngenedx.com/contact-us.\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.genedx.com%2Flong-read-sequencing-contact&esheet=54625240&newsitemid=20261020061134&lan=en-US&anchor=genedx.com%2Fcontact-us.&index=1&md5=b625d67011f3b13d9f0114c5782845f8)\n\nAbout GeneDx\n\nGeneDx’s (Nasdaq: WGS) mission is to empower everyone to live their\nhealthiest life through genomics. GeneDx combines unmatched clinical\nexpertise, advanced technology, and the power of GeneDx Infinity™ – the\nworld’s largest rare disease genomic dataset. This unparalleled foundation\npowers GeneDx’s ExomeDx™ and GenomeDx(®) tests – ranked #1 by expert\ngeneticists and granted FDA Breakthrough Device designation – enabling\nclinicians to deliver precise, fast, and actionable diagnoses. GeneDx Infinity\nalso fuels discovery for biopharma, with the most powerful AI-driven genomic\nintelligence. A genomics pioneer over the last 25 years, diagnosing more than\n4,800 genetic diseases and publishing more than 1,100 research publications,\nGeneDx is building the network that will drive the future of genomic precision\nmedicine. For more information, visit genedx.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.genedx.com%2F&esheet=54625240&newsitemid=20261020061134&lan=en-US&anchor=genedx.com&index=2&md5=51a8ca8c7e63846c3b95a5f2919abc21)\nand connect with us on LinkedIn\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fgenedx&esheet=54625240&newsitemid=20261020061134&lan=en-US&anchor=LinkedIn&index=3&md5=428c42f293a535b53cf7d80256a101d6)\n, Facebook\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.facebook.com%2FGeneDxLab%2F&esheet=54625240&newsitemid=20261020061134&lan=en-US&anchor=Facebook&index=4&md5=3d211ac135b526cff63cb8b708d8a3e0)\n, and Instagram\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.instagram.com%2Fgenedxlab&esheet=54625240&newsitemid=20261020061134&lan=en-US&anchor=Instagram&index=5&md5=1788bd247b029d309727e8bd49f60632)\n.\n\nForward Looking Statements\n\nThis press release may contain “forward-looking statements” within the\nmeaning of Section 21E of the Securities Exchange Act of 1934, as amended, and\nthe U.S. Private Securities Litigation Reform Act of 1995. These\nforward-looking statements generally are identified by the words\n“believe,” “project,” “expect,” “anticipate,” “estimate,”\n“intend,” “strategy,” “future,” “opportunity,” “plan,”\n“may,” “should,” “will,” “would,” “will be,” “will\ncontinue,” “will likely result,” and similar expressions.\nForward-looking statements are predictions, projections and other statements\nabout future events that are based on current expectations and assumptions\nand, as a result, are subject to risks and uncertainties. Many factors could\ncause actual future events to differ materially from the forward-looking\nstatements in this press release, including but not limited to: (i) our\nability to successfully launch new product offerings, (ii) the risk of\ndownturns and a changing regulatory landscape in the highly competitive\nhealthcare industry, (iii) the size and growth of the market in which we\noperate, and (iv) future expansion of insurance coverage for exome and genome\ntesting. The foregoing list of factors is not exhaustive. A further list and\ndescription of risks, uncertainties and other matters can be found in the\n“Risk Factors” section of our Annual Report on Form 10-K for the fiscal\nyear ended December 31, 2025 and our Quarterly Report on Form 10-Q for the\nfiscal quarter ended March 31, 2026, filed with the SEC on May 4, 2026, our\nQuarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2026,\nfiled with the SEC on August 3, 2026 and other documents filed by us from time\nto time with the SEC. These filings identify and address other important risks\nand uncertainties that could cause actual events and results to differ\nmaterially from those contained in the forward-looking statements.\nForward-looking statements speak only as of the date they are made. Readers\nare cautioned not to put undue reliance on forward-looking statements, and we\nassume no obligation and do not intend to update or revise these\nforward-looking statements, whether as a result of new information, future\nevents, or otherwise. We do not give any assurance that we will achieve our\nexpectations.\n 1. Devaney JM, Chong JX, Lopes PC, et al. Sensitivity of HiFi long-read genome  \n sequencing for difficult-to-detect pathogenic variants when applied to          \n real-world clinical laboratory samples. Am J Hum Genet. 2026                    \n Apr27:S0002-9297(26)00151-5.                                                    \n\n\n \n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20261020061134/en/\n(https://www.businesswire.com/news/home/20261020061134/en/)\n\nInvestors@GeneDx.com \n(mailto:Investors@GeneDx.com) \nPress@GeneDx.com (mailto:Press@GeneDx.com)\n\n\nCopyright Business Wire 2026","article_body_html":"","raw_payload":{"data":{"id":"nBwbktT25a-20261020","title":"GeneDx Expands Diagnostic Leadership with Long-Read Genome Sequencing, Advancing Rare Disease Diagnosis","author":"Business Wire","ticker":"WGS","created":"2026-10-20T12:30:00.323Z","tickers":["WGS"],"exchange":"NASDAQ","article_body":"GeneDx Expands Diagnostic Leadership with Long-Read Genome Sequencing,\nAdvancing Rare Disease Diagnosis\n\nGeneDx combines clinical expertise with a phenotype-driven approach to solve\ncomplex genetic cases and deliver answers sooner\n\nGeneDx (Nasdaq: WGS), the leader in rare disease diagnosis and improving\nhealth through the power of genomic data, today announced plans to enhance its\ngenome testing portfolio with long-read whole genome sequencing (lrWGS).\n\nLong-read sequencing analyzes longer stretches of DNA to identify complex\ngenetic variation, including certain structural variants and repeat expansions\nthat can go undetected by traditional short-read sequencing. With years of\npublished research(1) and collaborations with leading technology partners,\nGeneDx is uniquely positioned to bring long-read sequencing into clinical\npractice, combining advanced sequencing of genomic data, rich phenotypic data,\nand deep clinical expertise to deliver meaningful answers for patients.\n\nLeveraging insights from GeneDx Infinity™ and decades of clinical\ninterpretation, GeneDx will identify where long-read sequencing can deliver\nthe greatest diagnostic value and offer lrWGS upfront for eligible patients.\nThis targeted, phenotype-driven approach aims to reduce sequential testing,\nclose diagnostic gaps and accelerate diagnosis.\n\n“Long-read sequencing is providing us with substantially more powerful\ninsights into the human genome than previously possible. We are especially\ninterested in how this technology helps us to understand the cause of a\npatient’s rare disease when their genome is from a population that has been\nunder-studied,” said John Greally, D.Med., Ph.D., chief of genomics, and\nprofessor of genetics and pediatrics at Albert Einstein College of Medicine,\nclinical geneticist at the Children's Hospital at Montefiore (CHAM), and\nco-director of the NY Center for Rare Diseases at Montefiore. “The future\nfor rare disease diagnostics combines long-read sequencing with enhanced\nclinical information describing the patient, adding the expertise of\nclinicians to the solution, finally providing answers for patients and\nfamilies living with these conditions.”\n\n“Every advancement in genomic medicine should bring patients closer to\nanswers,” said Linda Genen, MD, MPH, Chief Medical Officer, GeneDx.\n“Long-read sequencing creates new opportunities to uncover complex genetic\nvariation, but the true value lies in how those findings are interpreted and\napplied. By combining advanced sequencing with our deep genomic data and\nclinical expertise, we aim to equip clinicians with clearer insights to\nnavigate complex cases, make more informed diagnostic decisions and get\npatients closer to answers.”\n\nThe early access program will be available by year-end and is part of GeneDx's\ncontinued focus on genome innovation to expand diagnostic capabilities and\ndeliver more answers to more patients. To learn more, contact our team at\ngenedx.com/contact-us.\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.genedx.com%2Flong-read-sequencing-contact&esheet=54625240&newsitemid=20261020061134&lan=en-US&anchor=genedx.com%2Fcontact-us.&index=1&md5=b625d67011f3b13d9f0114c5782845f8)\n\nAbout GeneDx\n\nGeneDx’s (Nasdaq: WGS) mission is to empower everyone to live their\nhealthiest life through genomics. GeneDx combines unmatched clinical\nexpertise, advanced technology, and the power of GeneDx Infinity™ – the\nworld’s largest rare disease genomic dataset. This unparalleled foundation\npowers GeneDx’s ExomeDx™ and GenomeDx(®) tests – ranked #1 by expert\ngeneticists and granted FDA Breakthrough Device designation – enabling\nclinicians to deliver precise, fast, and actionable diagnoses. GeneDx Infinity\nalso fuels discovery for biopharma, with the most powerful AI-driven genomic\nintelligence. A genomics pioneer over the last 25 years, diagnosing more than\n4,800 genetic diseases and publishing more than 1,100 research publications,\nGeneDx is building the network that will drive the future of genomic precision\nmedicine. For more information, visit genedx.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.genedx.com%2F&esheet=54625240&newsitemid=20261020061134&lan=en-US&anchor=genedx.com&index=2&md5=51a8ca8c7e63846c3b95a5f2919abc21)\nand connect with us on LinkedIn\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fgenedx&esheet=54625240&newsitemid=20261020061134&lan=en-US&anchor=LinkedIn&index=3&md5=428c42f293a535b53cf7d80256a101d6)\n, Facebook\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.facebook.com%2FGeneDxLab%2F&esheet=54625240&newsitemid=20261020061134&lan=en-US&anchor=Facebook&index=4&md5=3d211ac135b526cff63cb8b708d8a3e0)\n, and Instagram\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.instagram.com%2Fgenedxlab&esheet=54625240&newsitemid=20261020061134&lan=en-US&anchor=Instagram&index=5&md5=1788bd247b029d309727e8bd49f60632)\n.\n\nForward Looking Statements\n\nThis press release may contain “forward-looking statements” within the\nmeaning of Section 21E of the Securities Exchange Act of 1934, as amended, and\nthe U.S. Private Securities Litigation Reform Act of 1995. These\nforward-looking statements generally are identified by the words\n“believe,” “project,” “expect,” “anticipate,” “estimate,”\n“intend,” “strategy,” “future,” “opportunity,” “plan,”\n“may,” “should,” “will,” “would,” “will be,” “will\ncontinue,” “will likely result,” and similar expressions.\nForward-looking statements are predictions, projections and other statements\nabout future events that are based on current expectations and assumptions\nand, as a result, are subject to risks and uncertainties. Many factors could\ncause actual future events to differ materially from the forward-looking\nstatements in this press release, including but not limited to: (i) our\nability to successfully launch new product offerings, (ii) the risk of\ndownturns and a changing regulatory landscape in the highly competitive\nhealthcare industry, (iii) the size and growth of the market in which we\noperate, and (iv) future expansion of insurance coverage for exome and genome\ntesting. The foregoing list of factors is not exhaustive. A further list and\ndescription of risks, uncertainties and other matters can be found in the\n“Risk Factors” section of our Annual Report on Form 10-K for the fiscal\nyear ended December 31, 2025 and our Quarterly Report on Form 10-Q for the\nfiscal quarter ended March 31, 2026, filed with the SEC on May 4, 2026, our\nQuarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2026,\nfiled with the SEC on August 3, 2026 and other documents filed by us from time\nto time with the SEC. These filings identify and address other important risks\nand uncertainties that could cause actual events and results to differ\nmaterially from those contained in the forward-looking statements.\nForward-looking statements speak only as of the date they are made. Readers\nare cautioned not to put undue reliance on forward-looking statements, and we\nassume no obligation and do not intend to update or revise these\nforward-looking statements, whether as a result of new information, future\nevents, or otherwise. We do not give any assurance that we will achieve our\nexpectations.\n 1. Devaney JM, Chong JX, Lopes PC, et al. Sensitivity of HiFi long-read genome  \n sequencing for difficult-to-detect pathogenic variants when applied to          \n real-world clinical laboratory samples. Am J Hum Genet. 2026                    \n Apr27:S0002-9297(26)00151-5.                                                    \n\n\n \n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20261020061134/en/\n(https://www.businesswire.com/news/home/20261020061134/en/)\n\nInvestors@GeneDx.com \n(mailto:Investors@GeneDx.com) \nPress@GeneDx.com (mailto:Press@GeneDx.com)\n\n\nCopyright Business Wire 2026"},"type":"article","timestamp":"2026-10-20T12:30:00.390535238Z","server_sent_at_ms":1792499400390},"received_at":"2026-10-20T12:30:00.776Z","source_url":"https://www.businesswire.com/news/home/20261020061134/en/"},"analysis":{"id":"162041","press_release_id":"173972","analysis_json":{"industry":{"label":"Health Care Providers & Services","sector":"Health Care"},"redFlags":["no financial figures or revenue impact disclosed","launch timing and scope depend on forward-looking statements"],"eventType":"product_launch","narrative":"GeneDx announced plans to add long-read whole genome sequencing to its genome testing portfolio, targeting complex genetic variants such as structural variants and repeat expansions that short-read sequencing can miss.\n\nThe company says an early access program will be available by year-end and will use a phenotype-driven approach to offer lrWGS upfront for eligible patients, aiming to reduce sequential testing and accelerate rare disease diagnosis.\n\nNo financial details were disclosed, but the move reinforces GeneDx's rare-disease diagnostic moat, leveraging its Infinity dataset and FDA Breakthrough Device-designated ExomeDx and GenomeDx tests.","sentiment":"bullish","agentHooks":{"shouldPost":false,"suggestedAngle":"GeneDx extends its rare disease diagnostic lead into long-read sequencing, with early access by year-end -- a modest positive for its testing franchise."},"keyFigures":{"drugName":"","phaseOfTrial":"","customDimensions":{"research_publications":1100,"genetic_diseases_diagnosed":4800}},"quotedText":"Long-read sequencing is providing us with substantially more powerful insights into the human genome than previously possible.","namedEntities":{"people":[{"name":"John Greally, D.Med., Ph.D.","role":"chief of genomics, Albert Einstein College of Medicine; co-director, NY Center for Rare Diseases at Montefiore"},{"name":"Linda Genen, MD, MPH","role":"Chief Medical Officer, GeneDx"}],"products":["GeneDx Infinity","ExomeDx","GenomeDx","long-read whole genome sequencing (lrWGS)"],"companies":[{"name":"GeneDx","ticker":"WGS","relationship":"filer"},{"name":"Albert Einstein College of Medicine","relationship":"quoted institution"},{"name":"Montefiore / Children's Hospital at Montefiore (CHAM)","relationship":"quoted institution"}],"dollarAmounts":[]},"materialImpact":{"score":2,"reasoning":"Announcement of an expansion into long-read whole genome sequencing with an early access program by year-end. It strengthens GeneDx's diagnostic portfolio but includes no revenue figures, pricing, or hard guidance, so impact is modest."},"tickerRelevance":{"others":[],"primary":"WGS"},"globalImportance":25,"audienceRelevance":25,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap growth","eventGravity":"product/technology portfolio expansion without financials","sectorWeight":"genomic diagnostics","issuerAuthored":true}},"event_type":"product_launch","event_type_secondary":null,"sentiment":"bullish","material_impact_score":2,"narrative":"GeneDx announced plans to add long-read whole genome sequencing to its genome testing portfolio, targeting complex genetic variants such as structural variants and repeat expansions that short-read sequencing can miss.\n\nThe company says an early access program will be available by year-end and will use a phenotype-driven approach to offer lrWGS upfront for eligible patients, aiming to reduce sequential testing and accelerate rare disease diagnosis.\n\nNo financial details were disclosed, but the move reinforces GeneDx's rare-disease diagnostic moat, leveraging its Infinity dataset and FDA Breakthrough Device-designated ExomeDx and GenomeDx tests.","key_figures":{"drugName":"","phaseOfTrial":"","customDimensions":{"research_publications":1100,"genetic_diseases_diagnosed":4800}},"named_entities":{"people":[{"name":"John Greally, D.Med., Ph.D.","role":"chief of genomics, Albert Einstein College of Medicine; co-director, NY Center for Rare Diseases at Montefiore"},{"name":"Linda Genen, MD, MPH","role":"Chief Medical Officer, GeneDx"}],"products":["GeneDx Infinity","ExomeDx","GenomeDx","long-read whole genome sequencing (lrWGS)"],"companies":[{"name":"GeneDx","ticker":"WGS","relationship":"filer"},{"name":"Albert Einstein College of Medicine","relationship":"quoted institution"},{"name":"Montefiore / Children's Hospital at Montefiore (CHAM)","relationship":"quoted institution"}],"dollarAmounts":[]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:5c812bd9e28b810d","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-10-20T12:30:06.781Z","global_importance":25,"audience_relevance":25,"importance_components":{"tickerTier":"small-cap growth","eventGravity":"product/technology portfolio expansion without financials","sectorWeight":"genomic diagnostics","issuerAuthored":true}},"durationMs":null,"modelName":"glm-5.3-flashx"}}